Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | BAT7104 |
Synonyms | |
Therapy Description |
BAT7104 is a bispecific antibody that targets both CD47 and PD-L1 (CD274), which may lead to increased phagocytosis and enhanced cytotoxic T-lymphocyte (CTL) response against tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BAT7104 | BAT-7104|BAT 7104 | CD47 Antibody 30 Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 | BAT7104 is a bispecific antibody that targets both CD47 and PD-L1 (CD274), which may lead to increased phagocytosis and enhanced cytotoxic T-lymphocyte (CTL) response against tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05200013 | Phase I | BAT7104 | BAT7104 in Patients With Advanced Solid Tumours | Active, not recruiting | AUS | 0 |